Patient-, disease-, and transplantation-related characteristics
| Characteristic . | All patients, n (%) . | Matched sibling donor, n (%) . | URD, n (%) . | P . |
|---|---|---|---|---|
| No. of patients | 584 | 226 | 358 | |
| No. of centers | 151 | 94 | 102 | |
| Median age (range), y | 43 (< 1-74) | 40 (1-74) | 45 (< 1-73) | .01 |
| Age at transplantation, y | .02 | |||
| Younger than 20 | 88 (16) | 45 (20) | 43 (12) | |
| 20-49 | 296 (50) | 113 (50) | 183 (51) | |
| 50 or older | 200 (34) | 68 (30) | 132 (37) | |
| Male sex | 326 (56) | 132 (59) | 191 (53) | |
| Karnofsky score before HCT, < 90% | 136 (25) | 53 (23) | 83 (23) | |
| Missing | 38 | 4 | 34 | |
| WBC at diagnosis, ×109/L | ||||
| Median, range | 5.4 (< 1-700) | 6 (< 1-700) | 4.4 (< 1-354) | .02 |
| Less than 50 | 473 (86) | 176 (82) | 297 (88) | |
| 50 or more | 76 (14) | 38 (18) | 38 (12) | |
| Missing | 35 | 12 | 23 | |
| Extramedullary leukemia | 35 (6) | 18 (8) | 17 (5) | |
| CNS disease before transplantation | .004 | |||
| Yes | 14 (2) | 11 (5) | 3 (1) | |
| No | 570 (98) | 215 (95) | 355 (99) | |
| Therapy-related leukemia | ||||
| Yes | 84 (14) | 25 (11) | 59 (16) | |
| Missing | 5 | 4 | 1 | |
| Prior myelodysplasia | ||||
| Yes | 111 (19) | 35 (15) | 76 (21) | |
| Missing | 4 | 3 | 1 | |
| Time from diagnosis to transplantation, mo | ||||
| Median (range) | 5 (1-40) | 4 (1-40) | 5 (1-14) | < .001 |
| Less than 3 | 62 (11) | 35 (15) | 27 (8) | < .001 |
| 3-6 | 366 (63) | 149 (66) | 217 (61) | |
| 6-9 | 115 (20) | 30 (13) | 85 (24) | |
| More than 9 | 41 (7) | 12 (5) | 29 (8) | |
| Cytogenetics abnormality | < .001 | |||
| Complex (≥ 3 unrelated abnormalities) | 187 (32) | 41 (18) | 146 (41) | |
| Chromosome 7 abnormalities | 148 (25) | 55 (23) | 93 (26) | |
| Chromosome 5 abnormality | 58 (10) | 26 (12) | 32 (9) | |
| MLL gene rearrangement | 104 (18) | 55 (25) | 49 (13) | |
| t(6;9) | 28 (5) | 18 (8) | 10 (3) | |
| Other noncomplex abnormalities | 59 (10) | 31 (14) | 28 (8) | |
| Fungal infection anytime before HCT | ||||
| Yes | 102 (17) | 31 (14) | 71 (20) | |
| Missing | 8 | 6 | 3 | |
| Conditioning regimen | .004 | |||
| Myeloablative | 435 (74) | 183 (81) | 252 (70) | |
| Reduced intensity | 149 (26) | 43 (19) | 106 (30) | |
| Median donor age, y (range) | 35 (1-74) | 38 (1-74) | 34 (19-60) | .02 |
| Donor-recipient sex match | .03 | |||
| Male-male | 214 (37) | 79 (35) | 135 (38) | |
| Male-female | 155 (27) | 50 (22) | 105 (30) | |
| Female-male | 111 (19) | 56 (25) | 55 (15) | |
| Female-female | 102 (17) | 41 (18) | 61 (17) | |
| Missing | 2 | 0 | 2 | |
| Donor-recipient CMV serostatus | < .001 | |||
| +/+ | 153 (26) | 80 (37) | 73 (20) | |
| +/− | 60 (10) | 25 (12) | 35 (10) | |
| −/+ | 198 (36) | 54 (25) | 144 (41) | |
| −/− | 159 (28) | 57 (26) | 102 (29) | |
| Missing | 14 | 10 | 4 | |
| Type of donor | ||||
| HLA-identical sibling | 226 (39) | 226 (100) | 0 | |
| URD well-matched | 254 (43) | 0 | 254 (71) | |
| URD partially matched | 104 (18) | 0 | 104 (29) | |
| Graft type | ||||
| Bone marrow | 239 (41) | 89 (39) | 184 (44) | |
| Peripheral blood progenitor cells | 345 (59) | 137 (61) | 232 (56) | |
| Year of transplantation | < .001 | |||
| 1995-2000 | 160 (27) | 106 (47) | 54 (15) | |
| 2001-2006 | 424 (73) | 120 (53) | 304 (85) | |
| Growth factor used to promote engraftment | < .001 | |||
| Yes | 190 (39) | 73 (35) | 117 (42) | |
| No | 297 (61) | 136 (65) | 161 (58) | |
| Missing | 97 | 17 | 80 | |
| ATG given as conditioning or GVHD prophylaxis | 114 (20) | 18 (8) | 96 (27) | < .001 |
| GVHD prophylaxis | < .001 | |||
| CsA ± others | 292 (50) | 155 (68) | 137 (38) | |
| Tac ± others | 231 (40) | 40 (18) | 191 (53) | |
| T-cell depletion | 49 (8) | 20 (9) | 29 (8) | |
| Others/missing | 12 (2) | 11 (5) | 1 (1) | |
| Median follow-up of survivors, mo (range) | 44 (3-135) | 61 (3-131) | 35 (3-135) |
| Characteristic . | All patients, n (%) . | Matched sibling donor, n (%) . | URD, n (%) . | P . |
|---|---|---|---|---|
| No. of patients | 584 | 226 | 358 | |
| No. of centers | 151 | 94 | 102 | |
| Median age (range), y | 43 (< 1-74) | 40 (1-74) | 45 (< 1-73) | .01 |
| Age at transplantation, y | .02 | |||
| Younger than 20 | 88 (16) | 45 (20) | 43 (12) | |
| 20-49 | 296 (50) | 113 (50) | 183 (51) | |
| 50 or older | 200 (34) | 68 (30) | 132 (37) | |
| Male sex | 326 (56) | 132 (59) | 191 (53) | |
| Karnofsky score before HCT, < 90% | 136 (25) | 53 (23) | 83 (23) | |
| Missing | 38 | 4 | 34 | |
| WBC at diagnosis, ×109/L | ||||
| Median, range | 5.4 (< 1-700) | 6 (< 1-700) | 4.4 (< 1-354) | .02 |
| Less than 50 | 473 (86) | 176 (82) | 297 (88) | |
| 50 or more | 76 (14) | 38 (18) | 38 (12) | |
| Missing | 35 | 12 | 23 | |
| Extramedullary leukemia | 35 (6) | 18 (8) | 17 (5) | |
| CNS disease before transplantation | .004 | |||
| Yes | 14 (2) | 11 (5) | 3 (1) | |
| No | 570 (98) | 215 (95) | 355 (99) | |
| Therapy-related leukemia | ||||
| Yes | 84 (14) | 25 (11) | 59 (16) | |
| Missing | 5 | 4 | 1 | |
| Prior myelodysplasia | ||||
| Yes | 111 (19) | 35 (15) | 76 (21) | |
| Missing | 4 | 3 | 1 | |
| Time from diagnosis to transplantation, mo | ||||
| Median (range) | 5 (1-40) | 4 (1-40) | 5 (1-14) | < .001 |
| Less than 3 | 62 (11) | 35 (15) | 27 (8) | < .001 |
| 3-6 | 366 (63) | 149 (66) | 217 (61) | |
| 6-9 | 115 (20) | 30 (13) | 85 (24) | |
| More than 9 | 41 (7) | 12 (5) | 29 (8) | |
| Cytogenetics abnormality | < .001 | |||
| Complex (≥ 3 unrelated abnormalities) | 187 (32) | 41 (18) | 146 (41) | |
| Chromosome 7 abnormalities | 148 (25) | 55 (23) | 93 (26) | |
| Chromosome 5 abnormality | 58 (10) | 26 (12) | 32 (9) | |
| MLL gene rearrangement | 104 (18) | 55 (25) | 49 (13) | |
| t(6;9) | 28 (5) | 18 (8) | 10 (3) | |
| Other noncomplex abnormalities | 59 (10) | 31 (14) | 28 (8) | |
| Fungal infection anytime before HCT | ||||
| Yes | 102 (17) | 31 (14) | 71 (20) | |
| Missing | 8 | 6 | 3 | |
| Conditioning regimen | .004 | |||
| Myeloablative | 435 (74) | 183 (81) | 252 (70) | |
| Reduced intensity | 149 (26) | 43 (19) | 106 (30) | |
| Median donor age, y (range) | 35 (1-74) | 38 (1-74) | 34 (19-60) | .02 |
| Donor-recipient sex match | .03 | |||
| Male-male | 214 (37) | 79 (35) | 135 (38) | |
| Male-female | 155 (27) | 50 (22) | 105 (30) | |
| Female-male | 111 (19) | 56 (25) | 55 (15) | |
| Female-female | 102 (17) | 41 (18) | 61 (17) | |
| Missing | 2 | 0 | 2 | |
| Donor-recipient CMV serostatus | < .001 | |||
| +/+ | 153 (26) | 80 (37) | 73 (20) | |
| +/− | 60 (10) | 25 (12) | 35 (10) | |
| −/+ | 198 (36) | 54 (25) | 144 (41) | |
| −/− | 159 (28) | 57 (26) | 102 (29) | |
| Missing | 14 | 10 | 4 | |
| Type of donor | ||||
| HLA-identical sibling | 226 (39) | 226 (100) | 0 | |
| URD well-matched | 254 (43) | 0 | 254 (71) | |
| URD partially matched | 104 (18) | 0 | 104 (29) | |
| Graft type | ||||
| Bone marrow | 239 (41) | 89 (39) | 184 (44) | |
| Peripheral blood progenitor cells | 345 (59) | 137 (61) | 232 (56) | |
| Year of transplantation | < .001 | |||
| 1995-2000 | 160 (27) | 106 (47) | 54 (15) | |
| 2001-2006 | 424 (73) | 120 (53) | 304 (85) | |
| Growth factor used to promote engraftment | < .001 | |||
| Yes | 190 (39) | 73 (35) | 117 (42) | |
| No | 297 (61) | 136 (65) | 161 (58) | |
| Missing | 97 | 17 | 80 | |
| ATG given as conditioning or GVHD prophylaxis | 114 (20) | 18 (8) | 96 (27) | < .001 |
| GVHD prophylaxis | < .001 | |||
| CsA ± others | 292 (50) | 155 (68) | 137 (38) | |
| Tac ± others | 231 (40) | 40 (18) | 191 (53) | |
| T-cell depletion | 49 (8) | 20 (9) | 29 (8) | |
| Others/missing | 12 (2) | 11 (5) | 1 (1) | |
| Median follow-up of survivors, mo (range) | 44 (3-135) | 61 (3-131) | 35 (3-135) |
CNS indicates central nervous system; Tac, tacrolimus; CsA, cyclosporine A; and ATG, antithymocyte globulin.